Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1519

Sort by

Sort Order Select

Journal Articles

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Blood Adv (2025) 9 (15): 3665–3675.

https://doi.org/10.1182/bloodadvances.2024015180

Published: 2025

Includes: Supplemental data

Journal Articles

Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells

Léa Prévaud, Karima Ferhat, Dilara Sensoy, Ophélie Téteau, Tiffany Marchiol, Quentin Lemasson, Catherine Ouk, Claire Carrion, Michel Cogné, Jean Feuillard, Christelle Vincent-Fabert, Nathalie Faumont

Blood Adv (2025) 9 (15): 3676–3688.

https://doi.org/10.1182/bloodadvances.2023012166

Published: 2025

Includes: Supplemental data

Journal Articles

T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia

Julie Ma, Annie Luong, Andrew Doan, Tsen Yin Lin, Lingyun Ji, Cassandra P. Wang, Seon-Jae Yoon, Teresa Rushing, Anh Duong, Miguel Villa, Chintan Parekh

Blood Adv (2025) 9 (15): 3689–3693.

https://doi.org/10.1182/bloodadvances.2025015894

Published: 2025

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Blood Adv (2025) 9 (15): 3694–3705.

https://doi.org/10.1182/bloodadvances.2024015262

Published: 2025

Includes: Supplemental data

Journal Articles

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis

Joshua Fieggen, Anshul Thakur, Christopher C. Butler, Karthik Ramasamy, Anjan Thakurta, David A. Clifton, Lei Clifton

Blood Adv (2025) 9 (15): 3766–3770.

https://doi.org/10.1182/bloodadvances.2025016120

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O’Brien

Blood Adv (2025) 9 (15): 3801–3809.

https://doi.org/10.1182/bloodadvances.2024015417

Published: 2025

Journal Articles

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Alexey V. Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton, Karen Cumings, Viktor Chirikov, Alex Mutebi, Savreet Bains Chawla, Anindit Chhibber, Fernando Rivas Navarro, Felipe Marques Gonçalves, Anthony Wang, Zhijie Ding, Abualbishr Alshreef, Elena Favaro, Daniela Hoehn, Anna Sureda

Blood Adv (2025) 9 (15): 3754–3765.

https://doi.org/10.1182/bloodadvances.2024015274

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Blood Adv bloodadvances.2024015014.

https://doi.org/10.1182/bloodadvances.2024015014

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell Lymphoma

Blood Adv bloodadvances.2024015788.

https://doi.org/10.1182/bloodadvances.2024015788

Published: 2025

Includes: Supplemental data

Journal Articles

The IL7 receptor and the RAG complex are required for the onset of B-cell acute lymphoblastic leukemia

Audrey Dauba, Emmanuelle Näser, Antoine Nouhaud, Eric Delabesse, Bastien Gerby, Ahmed Amine Khamlichi

Blood Adv bloodadvances.2025016313.

https://doi.org/10.1182/bloodadvances.2025016313

Published: 2025

Includes: Supplemental data

Journal Articles

Molecular profiling of primary renal marginal zone lymphoma reveals overlapping features with extranodal marginal zone lymphoma

Axel Künstner, Vera von Kopylow, Philipp Lohneis, Matthias Kümmel, Hanno M. Witte, Veronica Bernard, Stephanie Stölting, Kathrin Kusch, Sivahari Gorantla, Manuela Krokowski, Nikolas von Bubnoff, Hartmut Merz, Hauke Busch, Alfred C. Feller, Niklas Gebauer

Blood Adv (2025) 9 (14): 3658–3663.

https://doi.org/10.1182/bloodadvances.2025016263

Published: 2025

Includes: Supplemental data

Journal Articles

Advances and updates in pediatric anaplastic large cell lymphoma

Lianna J. Marks, Eric J. Lowe, Kala Y Kamdar

Blood Adv bloodadvances.2025015935.

https://doi.org/10.1182/bloodadvances.2025015935

Published: 2025

Journal Articles

YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma

Vivian Jiang, Yu Xue, Hong Kim, Qingsong Cai, Tianci Zhang, Lei Nie, Joseph McIntosh, Yang Liu, Haiying Chen, Jia Zhou, Michael L Wang

Blood Adv bloodadvances.2025016511.

https://doi.org/10.1182/bloodadvances.2025016511

Published: 2025

Includes: Supplemental data

Journal Articles

Dual targeting of G9a and DNMTs induces anti-tumour effects in multiple myeloma

Patrick William Nylund, Berta Garrido-Zabala, Stefania Iliana Tziola, Tabassom Mohajershojai, Hanna Berglund, Catharina Muylaert, Lien Ann Van Hemelrijck, Alba Atienza Párraga, Louella Vasquez, Jim Jacob, Eric Bergquist, José-Ignacio Martín-Subero, Fredrik Öberg, Torbjörn Karlsson, Marika Nestor, Elke De Bruyne, Antonia Kalushkova, Helena Jernberg-Wiklund

Blood Adv bloodadvances.2023010571.

https://doi.org/10.1182/bloodadvances.2023010571

Published: 2025

Includes: Supplemental data

Journal Articles

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma

Khanmi Kasomva, Kritika Yadav, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood Adv bloodadvances.2025016829.

https://doi.org/10.1182/bloodadvances.2025016829

Published: 2025

Journal Articles

In vivo CRISPR screening reveals cooperation of KMT2D and TP53 deficiencies in B-cell lymphomagenesis

Blood Adv bloodadvances.2024015519.

https://doi.org/10.1182/bloodadvances.2024015519

Published: 2025

Includes: Supplemental data

Journal Articles

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Blood Adv bloodadvances.2025016651.

https://doi.org/10.1182/bloodadvances.2025016651

Published: 2025

Includes: Supplemental data

Journal Articles

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, John M. Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian Topp, Pallavi M Pillai, Alex F. Herrera

Blood Adv bloodadvances.2024014654.

https://doi.org/10.1182/bloodadvances.2024014654

Published: 2025

Includes: Supplemental data

Journal Articles

TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD EXPERIENCE FROM GELTAMO

Blood Adv bloodadvances.2025016661.

https://doi.org/10.1182/bloodadvances.2025016661

Published: 2025

Journal Articles

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome

Georgios Pongas, Maryam Alasfour, Daniel P. Cassidy, Juan P. Alderuccio, Joseph D. Rosenblatt, Izidore S. Lossos

Blood Adv (2025) 9 (14): 3594–3597.

https://doi.org/10.1182/bloodadvances.2025015913

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells

T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell Lymphoma

The IL7 receptor and the RAG complex are required for the onset of B-cell acute lymphoblastic leukemia

Molecular profiling of primary renal marginal zone lymphoma reveals overlapping features with extranodal marginal zone lymphoma

Advances and updates in pediatric anaplastic large cell lymphoma

YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma

Dual targeting of G9a and DNMTs induces anti-tumour effects in multiple myeloma

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma

In vivo CRISPR screening reveals cooperation of KMT2D and TP53 deficiencies in B-cell lymphomagenesis

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD EXPERIENCE FROM GELTAMO

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only